Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: A population-based study

Haematologica

Volumn 94, Issue 6, 2009, Pages 865-869

  Girodon, François ^a,b,d   Bonicelli, Gilles ^a   Schaeffer, Céline ^a   Mounier, Morgane ^b   Carillo, Serge ^c   Lafon, Ingrid ^a   Carli, Paule Marie ^b   Janoray, Inès ^b   Ferrant, Emmanuelle ^a   Maynadié, Marc ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d HÔPITAL DU BOCAGE   (France)

Author keywords

Essential thrombocythemia; Incidence; JAK2 mutation; Myeloproliferative neoplasm; Polycythemia vera

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; POLYCYTHEMIA; POPULATION RESEARCH; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FEMALE; FRANCE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; REGISTRIES; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 66749172267     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.004234     Document Type: Article

References (25)

1. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992;7:251-255
2. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ, 3rd. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 1994;47:89-93. (Pubitemid 24302276)
3. Johansson P, Kutti J, Andreasson B, Safai-Kutti S, Vilen L, Wedel H, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-1999. J Intern Med 2004;256:161-165
4. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006;32:171-173
5. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
6. Girodon F, Lippert E, Mossuz P, Dobo I, Boiret-Dupre N, Lesesve JF, et al. JAK2V617F detection and dosage of serum erythropoietin: first steps of the diagnostic work-up for patients consulting for elevated hematocrit. Haematologica 2007;92:431-432 (Pubitemid 350143561)
7. Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006;91:1400-1404 (Pubitemid 44569817)
8. Girodon F, Jooste V, Maynadie M, Favre B, Schaeffer C, Carli P. Incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the Cote d'Or area, France, during 1980-1999. J Intern Med 2005;258:90-91
9. Hemminki K, Zhang H, Sundquist J, Lorenzo Bermejo J. Myeloproliferative disorders in Sweden: Incidence trends and multiple tumors. Leuk Res 2009;33:e14-6.
10. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148 (Pubitemid 40663494)
11. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270. (Pubitemid 44125998)
12. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-468 (Pubitemid 46193073)
13. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
14. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-351
15. Jaffe ES HN, Stein H, Vardiman JW. World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues. IARC press ed. Lyon, France: World Health Organisation; 2001.
16. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2- V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865-1867 (Pubitemid 44394995)
17. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-139 (Pubitemid 30615089)
18. Cazzola M. Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis. Haematologica 2007;92:1585-1589 (Pubitemid 350248235)
19. Scott LM, Beer PA, Bench AJ, Erber WN, Green AR. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007;139:511-512 (Pubitemid 47512179)
20. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953 (Pubitemid 41713984)
21. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-1959. (Pubitemid 47299969)
22. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-4036 (Pubitemid 350248459)
23. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood 2006;108:2037-2040 (Pubitemid 44395018)
24. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008;93:1260-1261
25. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD, et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 2008;93:1723-1727